Biosergen AS (BIOSGN) - Net Assets
Based on the latest financial reports, Biosergen AS (BIOSGN) has net assets worth Skr8.12 Million SEK (≈ $873.52K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr21.16 Million ≈ $2.28 Million USD) and total liabilities (Skr13.04 Million ≈ $1.40 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Biosergen AS (BIOSGN) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr8.12 Million |
| % of Total Assets | 38.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | -59.88% |
| 10-Year Change | N/A |
| Growth Volatility | 986.47 |
Biosergen AS - Net Assets Trend (2019–2025)
This chart illustrates how Biosergen AS's net assets have evolved over time, based on quarterly financial data. Also explore BIOSGN total assets for the complete picture of this company's asset base.
Annual Net Assets for Biosergen AS (2019–2025)
The table below shows the annual net assets of Biosergen AS from 2019 to 2025. For live valuation and market cap data, see Biosergen AS (BIOSGN) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr8.12 Million ≈ $873.52K |
-83.48% |
| 2024-12-31 | Skr49.14 Million ≈ $5.29 Million |
+2222.35% |
| 2023-12-31 | Skr2.12 Million ≈ $227.72K |
-90.72% |
| 2022-12-31 | Skr22.79 Million ≈ $2.45 Million |
+12.66% |
| 2021-12-31 | Skr20.23 Million ≈ $2.18 Million |
+285.22% |
| 2020-12-31 | Skr-10.92 Million ≈ $-1.18 Million |
-132.84% |
| 2019-12-31 | Skr-4.69 Million ≈ $-504.90K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Biosergen AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3399491700.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Skr8.12 Million | 100.00% |
| Total Equity | Skr8.12 Million | 100.00% |
Biosergen AS Competitors by Market Cap
The table below lists competitors of Biosergen AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DGB Asia Bhd
KLSE:0152
|
$2.49 Million |
|
TT Electronics Plc
LSE:TTG
|
$2.49 Million |
|
Visionary Education Technology Holdings Group Inc.
NASDAQ:GV
|
$2.49 Million |
|
Odd Burger Corp
V:ODD
|
$2.49 Million |
|
Onfolio Holdings Inc
NASDAQ:ONFO
|
$2.49 Million |
|
NAYA Biosciences, Inc
NASDAQ:NAYA
|
$2.48 Million |
|
CDN Maverick Capital Corp.
F:338B
|
$2.48 Million |
|
PolyPlank publ AB
ST:POLY
|
$2.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biosergen AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 48,208,000 to 8,117,000, a change of -40,091,000 (-83.2%).
- Net loss of 40,817,000 reduced equity.
- Other factors increased equity by 726,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-40.82 Million | -502.86% |
| Other Changes | Skr726.00K | +8.94% |
| Total Change | Skr- | -83.16% |
Book Value vs Market Value Analysis
This analysis compares Biosergen AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | Skr-2.26 | Skr9.85 | x |
| 2020-12-31 | Skr-42.02 | Skr9.85 | x |
| 2021-12-31 | Skr37.83 | Skr9.85 | x |
| 2022-12-31 | Skr43.20 | Skr9.85 | x |
| 2023-12-31 | Skr4.71 | Skr9.85 | x |
| 2024-12-31 | Skr20.09 | Skr9.85 | x |
| 2025-12-31 | Skr3.46 | Skr9.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biosergen AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -502.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.61x
- Recent ROE (-502.86%) is below the historical average (-305.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -412.48% | 0.20x | 0.00x | Skr-4.95 Million |
| 2020 | 0.00% | -162.95% | 0.92x | 0.00x | Skr-6.13 Million |
| 2021 | -170.80% | -403.10% | 0.29x | 1.46x | Skr-36.58 Million |
| 2022 | -149.37% | 0.00% | 0.00x | 1.48x | Skr-36.33 Million |
| 2023 | -1277.74% | 0.00% | 0.00x | 3.40x | Skr-27.25 Million |
| 2024 | -39.82% | 0.00% | 0.00x | 1.10x | Skr-24.02 Million |
| 2025 | -502.86% | 0.00% | 0.00x | 2.61x | Skr-41.63 Million |
Industry Comparison
This section compares Biosergen AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,054,194
- Average return on equity (ROE) among peers: -81.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biosergen AS (BIOSGN) | Skr8.12 Million | 0.00% | 1.61x | $2.49 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About Biosergen AS
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.